First-line treatment in metastatic colorectal cancer: Important or crucial?

David Malka; Federico Rotolo; Valérie Boige

doi:10.1016/j.ejca.2017.09.001

First-line treatment in metastatic colorectal cancer: Important or crucial?

David Malka
, Federico Rotolo
, Valérie Boige

Institut Gustave Roussy
Université Paris-Saclay

Research output: Contribution to journal › Editorial

4 Scopus citations

Original language	English
Pages (from-to)	363-366
Number of pages	4
Journal	European Journal of Cancer
Volume	84
DOIs	https://doi.org/10.1016/j.ejca.2017.09.001
State	Published - Oct 2017
Externally published	Yes

Bibliographical note

Funding Information:
Dr. Malka reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees and non-financial support from Sanofi-Aventis, personal fees from Celgene, personal fees from Teva, personal fees from Boehringer-Ingelheim, personal fees from Menarini, personal fees and non-financial support from Merck Serono, personal fees from Bayer, personal fees from Lilly, personal fees from MSD, outside the submitted work; Dr. Boige reports grants from Merck Serono, personal fees from Daiichi Sankyo, Novartis, Roche and Prestizia, and personal fees and non-financial support from Merck Serono, Bayer, Amgen, and Sanofi-Aventis, outside the submitted work. DM reports personal fees from Amgen, Celgene, Teva, Boehringer-Ingelheim, Menarini, Bayer, Lilly, MSD, and personal fees and non-financial support from Roche, Sanofi-Aventis and Merck Serono, outside the submitted work.

Funding

Dr. Malka reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees and non-financial support from Sanofi-Aventis, personal fees from Celgene, personal fees from Teva, personal fees from Boehringer-Ingelheim, personal fees from Menarini, personal fees and non-financial support from Merck Serono, personal fees from Bayer, personal fees from Lilly, personal fees from MSD, outside the submitted work; Dr. Boige reports grants from Merck Serono, personal fees from Daiichi Sankyo, Novartis, Roche and Prestizia, and personal fees and non-financial support from Merck Serono, Bayer, Amgen, and Sanofi-Aventis, outside the submitted work. DM reports personal fees from Amgen, Celgene, Teva, Boehringer-Ingelheim, Menarini, Bayer, Lilly, MSD, and personal fees and non-financial support from Roche, Sanofi-Aventis and Merck Serono, outside the submitted work.

Funders
Amgen
Bayer
Roche
EMD Serono

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2017.09.001

Cite this

@article{8c11eab09ea34beb9b4702ad06759981,

title = "First-line treatment in metastatic colorectal cancer: Important or crucial?",

author = "David Malka and Federico Rotolo and Val{\'e}rie Boige",

note = "Funding Information: Dr. Malka reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees and non-financial support from Sanofi-Aventis, personal fees from Celgene, personal fees from Teva, personal fees from Boehringer-Ingelheim, personal fees from Menarini, personal fees and non-financial support from Merck Serono, personal fees from Bayer, personal fees from Lilly, personal fees from MSD, outside the submitted work; Dr. Boige reports grants from Merck Serono, personal fees from Daiichi Sankyo, Novartis, Roche and Prestizia, and personal fees and non-financial support from Merck Serono, Bayer, Amgen, and Sanofi-Aventis, outside the submitted work. DM reports personal fees from Amgen, Celgene, Teva, Boehringer-Ingelheim, Menarini, Bayer, Lilly, MSD, and personal fees and non-financial support from Roche, Sanofi-Aventis and Merck Serono, outside the submitted work. ",

year = "2017",

month = oct,

doi = "10.1016/j.ejca.2017.09.001",

language = "אנגלית",

volume = "84",

pages = "363--366",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - First-line treatment in metastatic colorectal cancer

T2 - Important or crucial?

AU - Malka, David

AU - Rotolo, Federico

AU - Boige, Valérie

N1 - Funding Information: Dr. Malka reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees and non-financial support from Sanofi-Aventis, personal fees from Celgene, personal fees from Teva, personal fees from Boehringer-Ingelheim, personal fees from Menarini, personal fees and non-financial support from Merck Serono, personal fees from Bayer, personal fees from Lilly, personal fees from MSD, outside the submitted work; Dr. Boige reports grants from Merck Serono, personal fees from Daiichi Sankyo, Novartis, Roche and Prestizia, and personal fees and non-financial support from Merck Serono, Bayer, Amgen, and Sanofi-Aventis, outside the submitted work. DM reports personal fees from Amgen, Celgene, Teva, Boehringer-Ingelheim, Menarini, Bayer, Lilly, MSD, and personal fees and non-financial support from Roche, Sanofi-Aventis and Merck Serono, outside the submitted work.

PY - 2017/10

Y1 - 2017/10

UR - https://www.scopus.com/pages/publications/85029632326

U2 - 10.1016/j.ejca.2017.09.001

DO - 10.1016/j.ejca.2017.09.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 28942867

AN - SCOPUS:85029632326

SN - 0959-8049

VL - 84

SP - 363

EP - 366

JO - European Journal of Cancer

JF - European Journal of Cancer